ストックスクリーナーアプリを入手
26.53
0.30%
0.08
プレマーケット:
26.64
0.11
+0.41%
前日終値:
$26.45
開ける：
$26.56
24時間の取引高:
40.12M
Relative Volume:
0.99
時価総額：
$151.21B
収益：
$63.32B
当期純損益:
$7.52B
株価収益率:
31.75
EPS:
0.8355
ネットキャッシュフロー:
$9.08B
1週間 パフォーマンス:
+1.03%
1か月 パフォーマンス:
-4.67%
6か月 パフォーマンス:
+6.76%
1年 パフォーマンス:
+15.95%
1日の値動き範囲:
$26.21
$26.68
1週間の範囲:
$26.01
$26.91
52週間の値動き範囲:
$21.97
$28.75
Pfizer Inc Stock (PFE) Company Profile
Compare PFE vs LLY, JNJ, ABBV, AZN, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
26.53 | 151.21B | 63.32B | 7.52B | 9.08B | 0.8355 |
LLY
Lilly Eli Co
|
987.05 | 880.19B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
224.62 | 540.71B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
205.03 | 362.65B | 62.82B | 3.62B | 17.82B | 2.0331 |
AZN
Astrazeneca Plc
|
184.92 | 286.78B | 60.48B | 10.40B | 8.05B | 3.3297 |
NVS
Novartis Ag Adr
|
148.36 | 283.08B | 54.66B | 13.58B | 16.05B | 7.0171 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-02 | アップグレード | Argus | Hold → Buy |
| 2026-02-25 | 開始されました | RBC Capital Mkts | Underperform |
| 2026-02-20 | 開始されました | Barclays | Underweight |
| 2026-02-12 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2026-01-07 | 再開されました | UBS | Neutral |
| 2025-12-02 | 再開されました | Citigroup | Neutral |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-11-15 | 開始されました | Wolfe Research | Underperform |
| 2024-10-25 | 再開されました | Citigroup | Neutral |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-08-07 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | ダウングレード | Argus | Buy → Hold |
| 2024-02-23 | 開始されました | Guggenheim | Buy |
| 2024-01-04 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | 再開されました | UBS | Neutral |
| 2023-10-16 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-17 | 繰り返されました | JP Morgan | Neutral |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-06-29 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | 開始されました | Jefferies | Hold |
| 2023-02-07 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | ダウングレード | UBS | Buy → Neutral |
| 2023-01-17 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-12-13 | アップグレード | Goldman | Neutral → Buy |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-04-06 | 再開されました | Morgan Stanley | Equal-Weight |
| 2022-01-05 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-01-03 | 繰り返されました | Bernstein | Mkt Perform |
| 2021-12-20 | 繰り返されました | Cowen | Outperform |
| 2021-12-17 | 開始されました | Goldman | Neutral |
| 2021-12-13 | アップグレード | UBS | Neutral → Buy |
| 2021-12-09 | 開始されました | Wells Fargo | Overweight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-05-06 | ダウングレード | Mizuho | Buy → Neutral |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | アップグレード | DZ Bank | Hold → Buy |
| 2020-12-16 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | 再開されました | Goldman | Neutral |
| 2020-11-10 | 再開されました | Bernstein | Mkt Perform |
| 2020-10-12 | ダウングレード | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-06-16 | 開始されました | SVB Leerink | Mkt Perform |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-02-27 | アップグレード | Standpoint Research | Hold → Buy |
| 2020-02-06 | 開始されました | Mizuho | Buy |
| 2020-01-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2019-10-17 | 再開されました | BofA/Merrill | Neutral |
| 2019-07-30 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | 再開されました | Morgan Stanley | Overweight |
| 2019-02-20 | 再開されました | Citigroup | Neutral |
| 2019-01-31 | アップグレード | Argus | Hold → Buy |
| 2019-01-31 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | ダウングレード | UBS | Buy → Neutral |
| 2018-12-11 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-11-01 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
すべてを表示
Pfizer Inc (PFE) 最新ニュース
Pfizer To Go Ex-Dividend On May 8th, 2026 With 0.43 USD Dividend Per Share - Moomoo
AI in Healthcare? Pfizer, Anthropic, and Longevity Scientists Think It’s Critical - Yahoo Finance
History Suggests These 3 Stocks Are Due for a Major Rebound - The Motley Fool
Tunica-Biloxi Tribe receives grant from Pfizer to expand healthcare in Central Louisiana - WGNO
Novavax (NVAX) Finds a New Revenue Engine in Pfizer Licensing - AlphaStreet
Pfizer’s newer medicines carry more weight in Q1 - thestreet.com
PFIZER INC : DZ Bank reiterates its Buy rating - marketscreener.com
Pfizer Q1 Earnings Beat: Should You Finally Buy PFE as Pharma Play? - Gotrade
PFIZER INC : UBS remains Neutral - marketscreener.com
Can Pfizer Stock Outrun A $17B Revenue Void? - Trefis
Novavax stock rises after Q1 2026 beat (NVAX:NASDAQ) - Seeking Alpha
Pfizer Inc. (NYSE:PFE) Q1 2026 Earnings Call Transcript - Insider Monkey
PFIZER INC : Jefferies reaffirms its Buy rating - marketscreener.com
FDA Appoints Szarama to CBER; Pfizer and Lilly Report Earnings - geneonline.com
Pfizer Q1 Revenue Rises 5% Despite Decline in Covid Products - thelec.net
Science Will Win season finale explores AI in cancer care with Pfizer Chief Oncology Officer Jeff Legos - Pfizer
Making Progress Against CancerFrom Cancer Research to Prevention and Screening - Pfizer
Cancer Treatments Propel Pfizer Sales Growth as Covid Revenue Dwindles - Yahoo Finance
Pfizer Quarterly Results Announcement: Revenue Forecasts and Market Sentiment | May 2026News and Statistics - IndexBox
Pfizer Earnings Call Highlights Growth Beyond COVID - TipRanks
Pfizer Gains Attention In Russell 1000 Index Momentum - Kalkine Media
Pfizer’s First PROTAC Approval Adds New Dimension To Oncology Story - simplywall.st
Pfizer CEO on Drug Pipeline, Trump's Pick to Lead CDC - marketscreener.com
Pfizer Oncology Advances Raise New Questions For Valuation And Momentum - Yahoo Finance
Pfizer Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Pfizer CEO Says Digging Out of Post-Covid Hole Will Take a Few More Years -- WSJ - Moomoo
Pfizer Earnings: Strong First-Quarter Performance Makes 2026 Guidance More Achievable - Morningstar
BofA raises Pfizer stock price target on first-quarter beat By Investing.com - Investing.com Canada
BofA raises Pfizer stock price target on first-quarter beat - Investing.com
Pfizer CEO Sees CDC Director Pick Restoring Agency’s Credibility - Bloomberg.com
Pfizer Beats Earnings Estimates. The Drugmaker Is Finding Life After Covid. - Barron's
PFIZER INC : JP Morgan reaffirms its Neutral rating - marketscreener.com
Pfizer Beats Sales Estimates As $17 Billion Patent Cliff Looms - GuruFocus
Pfizer pins post 2028 return to growth on new obesity and cancer drugs - Yahoo! Finance Canada
Research Alert: CFRA Lowers Rating On Shares Of Pfizer Inc. To Hold From Buy - Moomoo
Pfizer Q1 2026 slides: beats estimates on acquired assets strength - Investing.com
Pfizer Beats on Q1 Earnings, New & Acquired Drugs Drive Sales Growth - Yahoo Finance
Pfizer tops Q1 expectations on growth from newer products - MSN
Earnings call transcript: Pfizer Q1 2026 beats estimates, stock rises - Investing.com
Pfizer Says Vyndamax Drug Patent Settlement Reshapes Post-2028 Revenue View - Benzinga
Dow Jumps Over 300 Points; Pfizer Posts Upbeat Earnings - Benzinga
Pfizer Q1 Earnings Review: Stuck In Second Gear, But Dividend Helps (NYSE:PFE) - Seeking Alpha
Pfizer : Quarterly Corporate PerformanceFirst Quarter 2026 Presentation - marketscreener.com
Pfizer Inc. 2026 Q1ResultsEarnings Call Presentation (NYSE:PFE) 2026-05-05 - Seeking Alpha
Pfizer Tops First-Quarter Estimates, Reaffirms Full-Year Outlook - Moomoo
2 Trendlines in Focus For Pfizer Stock After Earnings - Schaeffer's Investment Research
Pfizer beats first quarter estimates on strong product growth - Investing.com
Pfizer tops sales estimates as older blockbusters outperform - Crain's New York Business
Q1 2026 Pfizer Inc Earnings Call Transcript - GuruFocus
Pfizer Tops Sales Estimates as Older Blockbusters Outperform - Bloomberg.com
Pfizer (PFE) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Pfizer Inc (PFE) 財務データ
収益
当期純利益
現金流量
EPS
2.11%
大文字化:
|
ボリューム (24 時間):